In early September 2026, two prominent cardiovascular drug development programs — one from Novartis and another from Novo Nordisk — reported failures or interruptions that attracted broad attention. The Novartis program, pelacarsen, was announced to have failed a widely watched, long-running clinical trial. Novo Nordisk stopped two cardiovascular trials of an anti-inflammatory drug. Coverage framed these developments as potentially influential beyond the individual programs, raising concerns about future investment and the momentum behind new cardiovascular treatment strategies.
Novartis’ therapy pelacarsen was designed to reduce cardiovascular events by lowering Lp(a), a lipid particle associated with increased risk of heart attack and stroke when present at elevated levels. The source notes that an estimated 20% of people have abnormally high Lp(a). Pelacarsen represented one of the first major clinical tests of the new generation of Lp(a)-targeting medicines, a class that multiple companies have pursued and into which industry players have invested substantial sums.
The STAT report states Novartis announced that pelacarsen failed in a seven-year clinical trial, but the publicly available portion of the article did not include detailed efficacy outcomes, numerical results, or specific reasons provided by Novartis for the failure. Those additional trial specifics and expanded analysis were part of the STAT+ subscriber content and are not present in the source excerpt.
Novo Nordisk discontinued two cardiovascular trials of a drug aimed at lowering inflammation, according to the source. The company halted those studies earlier in the same reporting period. The publicly available summary does not provide detailed trial data, stopping rationale, or the drug’s name within the excerpt. STAT’s coverage indicated the stopping of trials as a separate notable setback that followed closely on the heels of Novartis’ announcement.
The article frames the back-to-back setbacks as more than isolated failures: industry observers warned they could have a chilling effect on financing and development in cardiovascular research, especially for newcomers to the field. The coverage used the metaphor that these failures might “pop a hole in the balloon” of the field’s recent resurgence, indicating concern that investor enthusiasm and risk tolerance could decrease.
Several companies and investors had been committing large sums to programs targeting Lp(a) and inflammation pathways as potentially transformative approaches to preventing heart attacks and strokes. Because pelacarsen was among the first high-profile readouts testing the Lp(a) hypothesis at scale, its failure was presented as particularly consequential for companies exploring similar mechanisms.
The STAT excerpt highlights the risk that such high-profile negative results may make it harder to attract capital and corporate commitment for other cardiovascular candidates, even when the scientific rationale differs across programs.
The source places these announcements against a backdrop of renewed activity in cardiovascular drug development. Companies have been pursuing new mechanisms beyond conventional lipid-lowering therapies, including agents that lower Lp(a) and drugs that target inflammatory pathways implicated in atherosclerosis and cardiovascular events.
Novartis’ pelacarsen was described as the first major attempt at the Lp(a) approach, and multiple other companies were noted to be pursuing similar strategies. Novo Nordisk’s halted trials were among several efforts to test inflammation-targeting therapies for heart disease. The article suggests that the field had gained momentum, with significant R&D and financial commitments, prior to these setbacks.
This news item is identified as a STAT+ exclusive. The publicly accessible portion of the article provides a summary of the events, key context, the estimated prevalence of high Lp(a) (about 20%), and the suggestion that investor sentiment could be affected. However, the excerpt does not include detailed trial data, company statements with full technical explanations, numeric efficacy or safety results, or extended expert commentary that may appear in the full subscriber version.
For readers seeking granular trial readouts, precise stop reasons from Novo Nordisk, or in-depth analysis and named expert quotations beyond the framing provided here, the source indicates those materials were part of STAT+ subscriber content and were not reported in the publicly available excerpt.
Authors and date
The report is dated Sept. 11, 2026, and is by Allison DeAngelis and Adam Feuerstein. The story synthesizes the recent public announcements about Novartis and Novo Nordisk programs and situates them within broader trends in cardiovascular drug development.
Note on sourced facts
All facts and context above are drawn from the supplied STAT News article excerpt. Where the source excerpt omits numeric trial outcomes, detailed company rationales, drug names beyond pelacarsen, or extensive expert quotations, those specifics were not reported in the publicly available portion and are therefore not included here.